We are live on ! Find out more
NVS icon

Novartis

1,118 hedge funds and large institutions have $19.7B invested in Novartis in 2020 Q3 according to their latest regulatory filings, with 77 funds opening new positions, 346 increasing their positions, 458 reducing their positions, and 73 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more call options, than puts

Call options by funds: $178M | Put options by funds: $125M

5% more first-time investments, than exits

New positions opened: 77 | Existing positions closed: 73

0.46% less ownership

Funds ownership: 9.63%9.17% (-0.46%)

1% less funds holding

Funds holding: 1,1281,118 (-10)

5% less capital invested

Capital invested by funds: $20.7B → $19.7B (-$1.08B)

13% less funds holding in top 10

Funds holding in top 10: 1513 (-2)

24% less repeat investments, than reductions

Existing positions increased: 346 | Existing positions reduced: 458

Holders
1,118
Holders Change
-10
Holders Change %
-0.89%
% of All Funds
22.56%
Holding in Top 10
13
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-13.33%
% of All Funds
0.26%
New
77
Increased
346
Reduced
458
Closed
73
Calls
$178M
Puts
$125M
Net Calls
+$53.1M
Net Calls Change
-$42M
Name Holding Trade Value Shares
Change
Change in
Stake
Citigroup
101
Citigroup
New York
$19.1M +$45.1K +521 +0.2%
HTHT
102
Hemenway Trust Hemenway Trust
New Hampshire
$18.8M +$121K +1,402 +0.7%
LPL Financial
103
LPL Financial
California
$18.7M -$386K -4,454 -2%
William Blair & Company
104
William Blair & Company
Illinois
$18.2M +$1.13M +13,065 +7%
RMCM
105
Reynders McVeigh Capital Management
Massachusetts
$17.4M -$581K -6,705 -3%
GCC
106
Guardian Capital (Canada)
Ontario, Canada
$17.3M -$84.6K -977 -0.5%
MTC
107
McDaniel Terry & Co
Texas
$17.1M +$80.9K +934 +0.5%
Jane Street
108
Jane Street
New York
$17M +$2.57M +29,660 +18%
FFIC
109
First Fiduciary Investment Counsel
Ohio
$16.8M +$527K +6,081 +3%
RFA
110
Reilly Financial Advisors
California
$16.7M +$4.11M +47,402 +33%
EIA
111
Edgemoor Investment Advisors
Maryland
$16.4M -$251K -2,897 -2%
GHA
112
GW Henssler & Associates
Georgia
$15.4M +$500K +5,774 +3%
KFS
113
Kurt F. Somerville
$15.4M +$71.7K +828 +0.5%
NPF
114
Norris Perne & French
Michigan
$15.3M +$330K +3,804 +2%
Comerica Bank
115
Comerica Bank
Texas
$15.1M -$300K -3,464 -2%
BFS
116
Bradley Foster & Sargent
Connecticut
$15.1M +$15M +173,493 New
MIM
117
Martin Investment Management
Florida
$14.8M +$2.31M +26,700 +19%
GGI
118
Godsey & Gibb Inc
Virginia
$14.4M +$73.4K +847 +0.5%
BG
119
Bahl & Gaynor
Ohio
$14.3M -$448K -5,177 -3%
CIM
120
Corda Investment Management
Texas
$14.2M -$63.6K -734 -0.4%
Allianz Asset Management
121
Allianz Asset Management
Germany
$13.4M +$2.51K +29 +0%
TCM
122
Tekla Capital Management
Massachusetts
$13.2M -$1.69M -19,483 -11%
JGUA
123
John G. Ullman & Associates
New York
$13.2M -$86.6K -1,000 -0.7%
Rockefeller Capital Management
124
Rockefeller Capital Management
New York
$13.2M -$64.2M -740,514 -83%
CCM
125
Chilton Capital Management
Texas
$13.1M +$884K +10,200 +7%

NVS Hedge Fund Activity: Q3 2020 in Review

1,118 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2020, worth a combined $19.7B — down 5.2% from $20.7B a quarter earlier.

Buyers outnumbered sellers: 77 funds opened new NVS positions and 73 closed out — a net gain of 4 holders — while 346 added to existing stakes and 458 trimmed.

The largest buyer was Dodge & Cox, adding an estimated $211M. The largest seller was Brown Brothers Harriman & Co, cutting an estimated $313M.

  • 1,118 institutional investors held Novartis (NVS) as of Q3 2020, down from 1,128 in Q2 2020.
  • Funds reported $19.7B of Novartis stock for Q3 2020, down 5.2% quarter-over-quarter.
  • 77 funds opened new Novartis positions in Q3 2020 and 73 closed out, a net change of +4 holders.
  • The largest Novartis buyer in Q3 2020 was Dodge & Cox, an estimated $211M added.
  • The largest Novartis seller in Q3 2020 was Brown Brothers Harriman & Co, an estimated $313M sold.

Based on aggregated 13F filings for Q3 2020.